Novartis Pioneers New Direct-to-Patient Platform for Cosentyx

Novartis Unveils Direct-to-Patient Platform for Cosentyx

In an exciting development for patients in the United States, Novartis has announced the launch of a direct-to-patient (DTP) platform for their leading product, Cosentyx (secukinumab). This initiative aims to improve access and affordability for patients prescribed Cosentyx, allowing cash-paying individuals to purchase the medication at a 55% discount off the list price.

What is the DTP Platform?

The DTP platform is designed to provide a more straightforward purchasing process for patients, directly connecting them with Novartis and removing barriers typically associated with traditional healthcare pricing. Set to launch on November 1, 2025, this platform will initially focus on Cosentyx, which is well-known for its effectiveness in treating multiple immune-mediated inflammatory diseases, including psoriasis and psoriatic arthritis.

Victor Bultó, President, US for Novartis, emphasized the company’s commitment to innovation, stating, "Breakthrough innovation is what drives us at Novartis, in scientific research, medicine development, and in the ways in which we deliver our innovation to patients." This innovative approach illustrates their endeavor to enhance the healthcare experience for patients across America.

Impact on Patient Access and Affordability

The initiative not only showcases Novartis's commitment to patient care but also sets a precedent for how specialty medicines can be supplied in a more patient-friendly manner. By reflecting the average savings that insurers typically receive, the DTP platform serves as a proof-of-concept for a future model that could reshape how specialty medications are sold.

Furthermore, Novartis is exploring the possibility of extending this model to other suitable products in their portfolio, ensuring that more patients have access to essential medications at reduced costs. There are plans to develop a direct-to-business model, selling Cosentyx and potentially other medications to large employers, aiming to reduce costs and expand access for employees.

Support Programs for Patients

In addition to the DTP platform, Novartis has developed several assistance programs to aid patients in accessing Cosentyx. For those with commercial insurance, there are opportunities to pay as little as $0 for their prescriptions. Eligible patients undergoing the appeals process for coverage denials can receive the medication at no cost for up to two years.

The Novartis Patient Assistance Foundation, Inc. (NPAF) also plays a crucial role in supporting patients who are uninsured or cannot afford their medications. Through this independent non-profit organization, eligible patients may receive Cosentyx free of charge, embodying Novartis's dedication to patient-centric care.

Understanding Cosentyx (secukinumab)

Cosentyx is a fully-human biologic designed to target interleukin-17A, a crucial cytokine implicated in the inflammation associated with various immune-mediated inflammatory diseases. It holds approvals for treating adults with conditions such as psoriatic arthritis, moderate to severe plaque psoriasis, and others.

The drug's long-standing efficacy is supported by over ten years of data demonstrating its safety and effectiveness. Since its market introduction in 2015, more than 1.8 million patients worldwide have benefitted from its use, showcasing its global impact and acceptance. Moreover, it has received approvals in more than 100 countries, underscoring its significance in therapeutic treatment plans.

Committing to Continuous Improvement

Novartis's approach to healthcare is centered around continual improvement and understanding patient needs. The launch of the DTP platform represents an important milestone in this journey, as the company strives for transparency and accessibility within the healthcare system. By directly reaching patients, Novartis not only reinforces its commitment to innovation but also enhances the overall healthcare experience.

This forthcoming shift in medication accessibility highlights Novartis's vision to empower patients, allowing them to obtain the necessary treatments without unnecessary financial strain. The initiative could potentially inspire other pharmaceutical companies to consider similar models, paving the way for a more patient-focused industry.

Frequently Asked Questions

What is the direct-to-patient (DTP) platform?

The DTP platform allows cash-paying patients to buy Cosentyx directly from Novartis at a 55% discount off the list price.

When will the DTP platform be available?

The DTP platform is set to launch in the US on November 1, 2025.

How does the DTP platform affect patient costs?

It significantly reduces costs for patients, making medication more affordable by reflecting the average savings offered to insurers.

Are there assistance programs available for Cosentyx?

Yes, Novartis offers various assistance programs, including potential $0 copays for eligible patients with commercial insurance.

What conditions does Cosentyx treat?

Cosentyx is approved for multiple conditions, including psoriatic arthritis, psoriasis, and other immune-mediated inflammatory diseases.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.